{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:31:33Z","timestamp":1792812693769,"version":"4.5.0"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2011,12,14]],"date-time":"2011-12-14T00:00:00Z","timestamp":1323820800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0028973","type":"journal-article","created":{"date-parts":[[2011,12,14]],"date-time":"2011-12-14T20:27:02Z","timestamp":1323894422000},"page":"e28973","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":206,"title":["Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT\/mTOR Pathway"],"prefix":"10.1371","volume":"6","author":[{"given":"Mohammad","family":"Atefi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"von Euw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narsis","family":"Attar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deliang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Nazarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Chmielowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Glaspy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Begonya","family":"Comin-Anduix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Mischel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,12,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer.","volume":"417","author":"H Davies","year":"2002","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nature05661","article-title":"Melanoma biology and new targeted therapy.","volume":"445","author":"V Gray-Schopfer","year":"2007","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma.","volume":"363","author":"KT Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ncponc0558","article-title":"Mechanisms of disease: Oncogene addiction\u2013a rationale for molecular targeting in cancer therapy.","volume":"3","author":"IB Weinstein","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"611s","DOI":"10.1200\/jco.2010.28.15_suppl.8503","article-title":"Phase I\/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.","volume":"28","author":"R Kefford","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/sj.jid.5700026","article-title":"Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.","volume":"126","author":"VK Goel","year":"2006","journal-title":"J Invest Dermatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1535-7163.MCT-06-0084","article-title":"Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.","volume":"5","author":"KS Smalley","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.","volume":"467","author":"G Bollag","year":"2010","journal-title":"Nature"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation.","volume":"364","author":"PB Chapman","year":"2011","journal-title":"The New England journal of medicine"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"Abstr 8509","DOI":"10.1200\/jco.2011.29.15_suppl.8509","article-title":"BRIM-2: An Open-label, multicenter Phase II study of RG7204 (PLX4032) in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.","volume":"29","author":"A Ribas","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1158\/0008-5472.CAN-07-6787","article-title":"Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.","volume":"68","author":"C Montagut","year":"2008","journal-title":"Cancer Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/sj.bjc.6605714","article-title":"Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.","volume":"102","author":"KH Paraiso","year":"2010","journal-title":"Br J Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.","volume":"468","author":"R Nazarian","year":"2010","journal-title":"Nature"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K.","volume":"18","author":"J Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1479-5876-8-39","article-title":"Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific raf inhibitor PLX4032.","volume":"8","author":"JN Sondergaard","year":"2010","journal-title":"J Transl Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"12932","DOI":"10.1073\/pnas.0906606106","article-title":"The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.","volume":"106","author":"D Guo","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.","volume":"22","author":"TC Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ccr.2010.05.023","article-title":"4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors.","volume":"18","author":"QB She","year":"2010","journal-title":"Cancer Cell"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/sj.onc.1201000","article-title":"Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases.","volume":"14","author":"TC Grammer","year":"1997","journal-title":"Oncogene"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1158\/1078-0432.CCR-09-0872","article-title":"Inhibition of PI3K and MEK: it is all about combinations and biomarkers.","volume":"15","author":"BN Rexer","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.","volume":"468","author":"CM Johannessen","year":"2010","journal-title":"Nature"},{"key":"ref22","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2010.33.2312","article-title":"Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling.","author":"N Wagle","year":"2011"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.","volume":"2","author":"NP Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1158\/0008-5472.CAN-10-2954","article-title":"PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression.","volume":"71","author":"KH Paraiso","year":"2011","journal-title":"Cancer research"},{"key":"ref25","article-title":"MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720.","author":"CC Jiang","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.1890","article-title":"Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.","volume":"14","author":"JA Engelman","year":"2008","journal-title":"Nat Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1290\/0604027.1","article-title":"Life isn't flat: taking cancer biology to the next dimension.","volume":"42","author":"KS Smalley","year":"2006","journal-title":"In vitro cellular & developmental biology Animal"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"6670","DOI":"10.1158\/0008-5472.CAN-09-4471","article-title":"Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells.","volume":"70","author":"Y Shao","year":"2010","journal-title":"Cancer research"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1158\/0008-5472.CAN-04-1399","article-title":"Deregulated Akt3 activity promotes development of malignant melanoma.","volume":"64","author":"JM Stahl","year":"2004","journal-title":"Cancer research"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"8736","DOI":"10.1158\/0008-5472.CAN-10-0902","article-title":"Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.","volume":"70","author":"YN Gopal","year":"2010","journal-title":"Cancer research"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0028973","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T04:25:35Z","timestamp":1588998335000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0028973"}},"subtitle":[],"editor":[{"given":"Johanna M.","family":"Brandner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,12,14]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2011,12,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0028973","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,14]]}}}